scispace - formally typeset
G

Guillaume Butler-Laporte

Researcher at McGill University

Publications -  72
Citations -  1522

Guillaume Butler-Laporte is an academic researcher from McGill University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 10, co-authored 44 publications receiving 408 citations. Previous affiliations of Guillaume Butler-Laporte include Jewish General Hospital & McGill University Health Centre.

Papers
More filters
Journal ArticleDOI

How generalizable are randomized controlled trials (RCTs) in Staphylococcus aureus bacteremia? A description of the mortality gap between RCTs and observational studies.

TL;DR: In Staphylococcus aureus bacteremia, mortality rates in randomized controlled trials (RCTs) are consistently lower than observational studies, and clinicians should acknowledge the possibility of a lower treatment effect when applying RCT results to bedside care.
Journal ArticleDOI

The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

Guillaume Butler-Laporte, +227 more
- 28 Sep 2022 - 
TL;DR: In this article , the authors measured 147 immune-related proteins during acute COVID-19 to investigate the differences in outcomes between sexes between severe cases and controls, adjusting for age and sex.
Journal ArticleDOI

Dehydration is associated with production of organic osmolytes and predicts physical long-term symptoms after COVID-19: a multicenter cohort study

TL;DR: In this article , the validity of the physiological response to dehydration known as aestivation and its relevance for long-term disease outcome in COVID-19 patients was evaluated using data from the Pronmed cohort admitted to Uppsala University Hospital.
Journal ArticleDOI

Targeted caspofungin prophylaxis for invasive aspergillosis in high‐risk liver transplant recipients, a single center experience

TL;DR: In this article, the authors conducted a single center, retrospective, before and after cohort study, comparing IA incidences among OLTr who did not receive antifungal prophylaxis after transplantation (cohort 1) to OLTs who received targeted antIFungal pre-treatment after liver transplantation, and the primary outcome was IA at 90 days after transplant.